Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 2;44(2):176-185.
doi: 10.1002/clc.23520. Online ahead of print.

Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention

Affiliations

Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention

Zhuoshan Huang et al. Clin Cardiol. .

Abstract

Recent studies and guidelines have indicated that lipoprotein(a) [Lp(a)]was an independent risk factor of arteriosclerotic cardiovascular disease (ASCVD). This study aimed to determine the relationship between serum Lp(a) levels and the risk of periprocedural myocardial injury following percutaneous coronary intervention (PCI) in coronary heartdisease (CHD) patients. This study enrolled 528 nonacute myocardial infarction (AMI) coronary heart disease (CHD) patients who successfully underwent PCI. Fasting serum lipids including Lp(a) were tested before PCI. High-sensitivity cardiac troponin I (hs-cTnI) was tested before PCI and 24 h after PCI. Univariate and multivariate logistic regression analyses were used to determine the relationship between preprocedural Lp(a) levels and postprocedural cTnI elevation from 1 × upper limit of normal (ULN) to 70 × ULN. As a continuous variable, multivariate analyses adjusting for conventional covariates and other serum lipids revealed that increased Lp(a) levels were independently associated with the risk of elevated postprocedural cTnI values above 1 × ULN (odds ratio [OR] per log-unit higher: 1.31, 95% confidence interval [CI]: 1.02-1.68, P = 0.033], 5 × ULN (OR: 1.25, 95%CI: 1.02-1.53, P = 0.032), 10 × ULN (OR: 1.48, 95%CI: 1.18-1.86, P = 0.001) and 15 × ULN (OR: 1.28, 95%CI: 1.01-1.61, P = 0.038). As a categorical variable, Lp(a) > 300 mg/L was an independent risk factor of postproceduralc TnI≥1 × ULN (OR 2.17, 95%CI 1.12-4.21, P = 0.022), ≥5 × ULN (OR 1.82, 95%CI 1.12-2.97, P = 0.017) and ≥10 × ULN (OR 2.17, 95%CI 1.33-3.54, P = 0.002). Therefore, it could be concluded that elevated preprocedural Lp(a) levels were associated with the risk of PCI-related myocardial injury in non-AMI CHD patients.

Keywords: high‐sensitivity cardiac troponin I; lipoprotein(a); percutaneous coronary intervention; periprocedural myocardial injury.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interests.

Figures

FIGURE 1
FIGURE 1
Flowchart illustrating study population. CHD, coronary heart disease; PCI, percutaneous coronary intervention; AMI, acute myocardial infarction
FIGURE 2
FIGURE 2
Distribution of Lp(a) levels and ln[Lp(a)] levels in the study population
FIGURE 3
FIGURE 3
Univariate logistic regression analysis results of correlation between preprocedural serum Lp(a) and postprocedural cTnI elevations. OR, odds ratio; ULN, upper limit of normal. #Results of continuous Lp(a) were represented by OR per log‐unit increase. *The association between Lp(a) > 300 mg and postprocedural cTnI≥70 × ULN was not investigated because of the small sample size

Similar articles

Cited by

References

    1. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692‐711. - PubMed
    1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111‐188. - PubMed
    1. Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, Ala‐Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta. 2000;1488(3):189‐210. - PubMed
    1. Cholesterol Treatment Trialists' (CTT) Collaboration , Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‐analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670‐1681. - PMC - PubMed
    1. Emerging Risk Factors Collaboration , Di Angelantonio E, Gao P, et al. Lipid‐related markers and cardiovascular disease prediction. Jama. 2012;307(23):2499‐2506. - PMC - PubMed